Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. - Wikidata - wikimedia - TriplyDB

Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.

Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.

http://www.wikidata.org/entity/Q34276216

about

Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention Stroke prevention in atrial fibrillation--things can only get better An exception that proves the rule: recurrence free survival five years after extrapleural pneumonectomy for malignant pleural mesothelioma The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey.National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries Medication adherence: process for implementation Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians.Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly?The increasing prevalence of atrial fibrillation among hemodialysis patients.Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation.Study protocol: the DESPATCH study: delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare Percutaneous closure of the left atrial appendage for secondary prevention of stroke in patients with atrial fibrillation and contraindications to chronic anticoagulant therapy Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance.Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis.Warfarin usage among elderly atrial fibrillation patients with traumatic injury, an analysis of United States Medicare fee-for-service enrollees Supporting Treatment decision making to Optimise the Prevention of STROKE in Atrial Fibrillation: the STOP STROKE in AF study. Protocol for a cluster randomised controlled trial.Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach.The risks of warfarin use in the elderly.Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004 Relationship between polypharmacy and underprescribing.Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States.Clinical pharmacology in the geriatric patient.Should anticoagulation be resumed after intracerebral hemorrhage?Use of genetic and nongenetic factors in warfarin dosing algorithms.Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label.Clinical pharmacology in old persons.A system dynamics model of clinical decision thresholds for the detection of developmental-behavioral disorders The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China.Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation.Cognitive biases and heuristics in medical decision making: a critical review using a systematic search strategy.Underuse of anticoagulation in patients with atrial fibrillation.Assessing surgeon behavior change after anastomotic leak in colorectal surgery.A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Personal knowledge.Barriers to using warfarin in non-valvular atrial fibrillation.Clinical usefulness in geriatric patients of combining CHADS2 and HEMORR2HAGES scores to guide antithrombotic prophylaxis in atrial fibrillation.Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.Comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial on prescribing patterns: a time-series analysis.

P2860

Q28069809-B14CFB2F-A95E-4B68-ABD1-DBB539081FFD Q28213581-89D78462-D588-4A1D-B8EF-98157F697A2B Q28651771-322AF30A-4E4F-4297-91D1-4E9AC3BA8A3F Q33384911-D133351F-8CCC-4179-AE09-64202C1FB288 Q33553982-9D41343C-E013-4098-A394-66EF9E49B738 Q34005496-B68A6647-0B1A-4060-B5BE-8F4E98DA4978 Q34087971-6497DF80-E1A8-4992-846E-55A8FD4F9D30 Q34245296-FA6F0752-C9B0-49D4-8917-F9C53FCD876D Q34534916-930EBC53-B04B-4D34-90B8-37DC2F42C15C Q34551073-67DA4B13-75F5-403E-863D-0AF681B1315F Q35063716-63105F6D-28F8-4A93-8217-E2EAA1C64EC3 Q35214491-C26E0EDB-CBD5-42B9-87DF-6CB9875F8575 Q35575180-88679EAB-3B55-49F9-98BE-F25441A06064 Q35800190-D2FB1E5C-3B65-4A41-A1B2-EB208026B1BB Q35846455-96BF05C5-4787-43D2-8D07-FC26D564BC22 Q36062288-2178CF25-8A0D-4B58-BADB-13C04016D55A Q36235962-61A23CFA-6BF4-4C72-98BB-ADEC9A10FA3E Q36409072-C301AC12-B5F7-43B0-AB61-0F3F92A20DAA Q36446904-225189B8-A21D-41CA-B22E-17F9E3063643 Q36468237-DEF90E85-F499-4521-9BAD-5762C1E2BD32 Q36536061-F2F54AAF-0FB0-4457-8217-A7A3406F2F30 Q36808315-3DD05470-B73B-4FE3-B07F-FB7AD4A29161 Q36830192-CCAAF0B7-25EA-437A-BFE9-2639832145FE Q36933765-435B25D5-A8A6-4CD2-AE6F-212571FA3A34 Q37074097-39F095A8-8572-4F70-A212-859880041A2A Q37160357-26BB646D-B71E-40A8-BBEE-207FFC765883 Q37288132-25D2C5D1-EC48-4A41-8A3D-C91DEA6F2F9F Q37440066-8AB81A1C-F1FC-469C-B7C3-F8EBE74984C2 Q37693764-1C296737-C3C8-4F7B-AA25-B31B5C688EE4 Q38097727-359029FD-47BE-41B2-A82C-104D207F3388 Q38242008-4832BB9E-C6B8-4FC2-B347-A0E8587D0A7D Q38668964-2A14284C-3E77-4181-8FE8-038A8384128F Q39354683-026F7027-7CAD-49F9-8511-57D0693EDE49 Q39773766-FBE6C096-02AB-44CD-AD76-2EF74EAED9C2 Q40174813-0882DEF9-8E5F-40B5-9652-24C5E17137C9 Q43167083-0331EC08-47F2-4A5F-B92D-41A8D5042F9C Q43197156-20F374F4-C34D-4C08-8E2E-4D3C15BDB6FF Q43227133-87C8F52D-51BC-4003-A223-789EB7B070EE Q43831345-46D9FACC-3881-436C-8973-8798D02FE6F0 Q44113148-5B8FC295-AB62-46C0-B2DD-B0CBBD8363BF

P2860

Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.

http://www.wikidata.org/entity/Q34276216

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Impact of adverse events on pr ...... lation: matched pair analysis.

@ast

Impact of adverse events on pr ...... lation: matched pair analysis.

@en

Impact of adverse events on pr ...... lation: matched pair analysis.

@nl

type

label

Impact of adverse events on pr ...... lation: matched pair analysis.

@ast

Impact of adverse events on pr ...... lation: matched pair analysis.

@en

Impact of adverse events on pr ...... lation: matched pair analysis.

@nl

prefLabel

Impact of adverse events on pr ...... lation: matched pair analysis.

@ast

Impact of adverse events on pr ...... lation: matched pair analysis.

@en

Impact of adverse events on pr ...... lation: matched pair analysis.

@nl

P1433

Q34276216-3266DFEB-F1C9-4704-B547-3291AC828AE2

P1476

Q34276216-F44ED7C8-218E-4B9B-BA5C-D2313CBB8573

P2093

Q34276216-20797E96-CCE9-4A36-A448-1F701A042FB1

Q34276216-2B6DD8CF-E562-4336-837B-901538B35E36

Q34276216-760C1063-6429-4338-A99C-F0D452734ECC

Q34276216-DD8D90FE-099D-4C01-A012-ABA944A3B8DF

Q34276216-F1619DF7-9115-4FEE-AD73-8EF01131B11F

P2860

Q34276216-04E79878-DA79-4CD1-B1E8-46247242DCEB

Q34276216-0C620390-2361-4B29-A5FC-B8582C231865

Q34276216-154E4E2E-0373-4B1E-895E-3F6001869455

Q34276216-35BD9484-F5C0-45DE-B79B-9660F816F953

Q34276216-3D9BDA28-DA50-4DB4-8927-94FD1B193378

Q34276216-3F1CBCAD-C64B-4D30-A6DE-D2C7271C75D8

Q34276216-455FFD72-17A3-49CA-B5F4-9484067A410A

Q34276216-469797A7-2AFC-4C50-95B6-F4BBC9E83AF6

Q34276216-4B5D6F90-E25D-4086-B97A-CDDFE719AAEC

Q34276216-5E104687-E2A0-406E-89BD-0B11DC1CEF4E

P304

Q34276216-BF155ED7-1DFB-450D-A1BA-E97BFA516526

P31

Q34276216-9C4C0110-FA7A-4752-9452-D75BA16E42F4

P356

Q34276216-9D1F250E-97F9-45A2-88E0-7F1AAB014867

P407

Q34276216-FF88697E-35FD-42A7-B8D0-86BBB5F1E694

P433

Q34276216-B3F94C3D-29C0-443E-9C52-D13F544DCD8E

P478

Q34276216-A77D4863-E4CD-4BA4-AECA-A781F124BB3E

P50

Q34276216-43FF4949-02FE-4560-9C2B-10DB3E9EE73E

P577

Q34276216-B3CE8FEF-1940-4961-A278-85B5E6A8FA92

P5875

Q34276216-2622C768-709A-4B1B-BEB0-74EDFA3AF353

P698

Q34276216-2B076DA7-18D2-4CB5-9F6A-876A6653676E

P921

Q34276216-DA799005-428F-40C7-9A94-AC61B225A086

Q34276216-DC1D7DB0-BAAA-42CE-B79B-11B29CC96702

P932

Q34276216-AC93098E-B299-49CF-87B3-18FA955183B6

P356

BMJ.38698.709572.55

P1433

P1476

Impact of adverse events on pr ...... lation: matched pair analysis.

@en

P2093

Andreas Laupacis

http://www.w3.org/2001/XMLSchema#string

Geoffrey M Anderson

http://www.w3.org/2001/XMLSchema#string

Niteesh K Choudhry

http://www.w3.org/2001/XMLSchema#string

Sharon-Lise T Normand

http://www.w3.org/2001/XMLSchema#string

Stephen B Soumerai

http://www.w3.org/2001/XMLSchema#string

P2860

Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Judgment under Uncertainty: Heuristics and Biases

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Validating administrative data in stroke research.

Evidence of self-report bias in assessing adherence to guidelines.

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.

Why do patients with atrial fibrillation not receive warfarin?

Why general practitioners do not implement evidence: qualitative study

Mortality among patients admitted to hospitals on weekends as compared with weekdays.

P304

141-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.38698.709572.55

http://www.w3.org/2001/XMLSchema#string

P407

P433

7534

http://www.w3.org/2001/XMLSchema#string

P478

332

http://www.w3.org/2001/XMLSchema#string

P50

Dennis Ross-Degnan

P577

2006-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7367788

http://www.w3.org/2001/XMLSchema#string

P698

16403771

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

1336760

http://www.w3.org/2001/XMLSchema#string